Suggested remit: To appraise the clinical and cost effectiveness of osimertinib within its marketing authorisation as maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung cancer (NSCLC) which has not progressed after platinum based chemoradiation.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6223

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6223 10 July 2024 - 07 August 2024

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 July 2024 In progress. Scoping commencing
14 March 2024 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late October 2024 when we will write to you about how you can get involved.
26 January 2024 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
31 July 2023 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-July 2024.
16 December 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
28 November 2022 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual